Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan.
Int J Urol. 2022 Mar;29(3):206-211. doi: 10.1111/iju.14750. Epub 2021 Dec 12.
Post-transplant lymphoproliferative disorder is a potentially life-threatening complication that has a greater risk of occurrence in the setting of immunosuppression and oncogenic viral infections after transplant surgery. Few studies have reported the cumulative incidence, histological subtypes and clinical outcomes of this disorder in kidney transplant recipients.
We retrospectively investigated 34 post-transplant lymphoproliferative disorder patients diagnosed out of the 1210 kidney transplant recipients who had undergone the surgery at the two largest centers in Japan between January 1983 and December 2017.
A total of 32 patients (94.1%) developed late-onset post-transplant lymphoproliferative disorder (diagnosed 1 year after transplantation). The cumulative incidence rates were 0.76% and 1.59% at 5 and 10 years post-transplantation, respectively. The central nervous system was the most common site (35.3%, 12/34). Overall survival was similar between patients with and without central nervous system lesions (P = 0.676). Of all of the cases, 23.5% (8/34) were detected through cancer screening. Importantly, patients with screening-detected post-transplant lymphoproliferative disorder had better overall survival than those with the disorder who had been symptom detected (P = 0.0215). Overall survival was significantly reduced in patients who developed the disorder compared with those who did not (P = 0.0001).
Post-transplant lymphoproliferative disorder was more likely to occur in the late post-transplantation period, which showed that long-term medical examination for transplant recipients is required. Based on our findings, we propose vigilant, long-term, cancer screening in kidney transplant recipients.
移植后淋巴组织增生性疾病是一种潜在的危及生命的并发症,在移植手术后免疫抑制和致癌病毒感染的情况下发生风险更高。少数研究报告了肾移植受者中这种疾病的累积发生率、组织学亚型和临床结果。
我们回顾性调查了 1983 年 1 月至 2017 年 12 月期间在日本最大的两个中心接受手术的 1210 例肾移植受者中诊断出的 34 例移植后淋巴组织增生性疾病患者。
共有 32 例(94.1%)发生迟发性移植后淋巴组织增生性疾病(移植后 1 年诊断)。移植后 5 年和 10 年的累积发生率分别为 0.76%和 1.59%。中枢神经系统是最常见的部位(35.3%,12/34)。有和没有中枢神经系统病变的患者的总生存率相似(P=0.676)。所有病例中,23.5%(8/34)是通过癌症筛查发现的。重要的是,筛查发现的移植后淋巴组织增生性疾病患者的总生存率优于症状发现的患者(P=0.0215)。与未发生该疾病的患者相比,发生该疾病的患者的总生存率显著降低(P=0.0001)。
移植后淋巴组织增生性疾病更可能发生在移植后晚期,这表明需要对移植受者进行长期的医学检查。根据我们的发现,我们建议对肾移植受者进行警惕、长期的癌症筛查。